Proposed Public Offer of IMRN ADSs
Filed with ASX · · 2 pages · English
Earlier from Immuron
- Immuron North American revenue surges by 52% in FY19
- US DoD Reports Results from Travelan Shigellosis Study
- Preliminary Prospectus Supplement filed with SEC
- Trading halt
- Immuron Appoints CEO Dr. Gary S. Jacob to Board of Directors
Later from Immuron
- Immuron Prices Underwritten Public Offering of ADSs
- Underwritten Public Offer
- Immuron Reports Results in SAH Clinical Trial
- Appendix 4E & Annual Report to shareholders
- US Defense Reports Immuron Travelan Targets Cholera
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron